|
Interagency Committee on Human Growth Hormone
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NICHD, NIDDK, NINDS
|
The committee was instituted to follow up recipients of human growth hormone derived from pituitary glands that was distributed by NIH under and IND.
|
|
Interagency Committee on Smoking and Health
|
Committee, Work group, Advisory group, or Task Force
|
CDC, HRSA
|
NICHD, NCI, NHLBI, NIDA
|
The Interagency Committee on Smoking and Health (ICSH) coordinates Department of Health and Human Services research, educational programs, and other smoking and health effects with similar activities of other federal, state, local, and private agencies.
|
|
Interagency Coordinating Committee on Fetal Alcohol Spectrum Disorders (ICCFASD)
|
Committee, Work group, Advisory group, or Task Force
|
ACF, AHRQ, CDC, HRSA, IHS, SAMHSA
|
NIAAA, NICHD
|
The ICCFASD was created in October 1996 in response to recommendations of an expert committee of the Institute of Medicine that NIAAA chair an effort to coordinate Federal activities on fetal alcohol syndrome (FAS) and other disorders associated with prenatal alcohol exposure. The ICCFASD works to improve communication, cooperation, and collaboration among disciplines and federal agencies that address issues of health, education, developmental disability, research, justice, and social services relevant to FAS and related disorders caused by prenatal alcohol exposure. The ICCFASD meets twice a year and frequently arranges special conferences; the most recent was Oct. 31-Nov. 2, 2011 on Recognizing Alcohol-related neurodevelopmental disorder (ARND) in Primary Health Care of Children.
|
|
Interagency Coordinating Committee on Human Growth Hormone and Creutzfeldt-Jakob Disease
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NIDDK, NICHD, NINDS
|
Coordinates federal efforts to understand how pituitary human growth hormone may have led to the development of Creutzfeldt-Jakob Disease in participants of the National Hormone and Pituitary Program.
|
|
Interagency Coordinating Committee on the Prevention of Underage Drinking (ICCPUD)
|
Committee, Work group, Advisory group, or Task Force
|
ACF, CDC, IHS, OS, OSG, SAMHSA
|
NIDA, NIAAA
|
The Consolidated Appropriations Act of 2004 directed the Secretary of Health and Human Services (HHS) to establish the Interagency Coordinating Committee on the Prevention of Underage Drinking (ICCPUD) and to issue an annual report summarizing all Federal agency activities related to preventing underage alcohol use. HHS made ICCPUD a standing committee to provide ongoing, high-level leadership on this issue and to serve as a mechanism for coordinating Federal efforts aimed at preventing and reducing underage drinking. The Substance Abuse and Mental Health Services Administration (SAMHSA) serves as the lead ICCPUD agency.
|
|
Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM)
|
Research Initiative
|
ATSDR, CDC, FDA
|
NIEHS, NCI, NEI, NIAID, NLM
|
The Interagency Coordinating Committee on the Validation of Alternative Methods is an interagency committee of 15 Federal agencies that carries out specific duties prescribed by the ICCVAM Authorization Act, P.L. 106-545. The ICCVAM is administered by the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM), a component of the NIEHS. NICEATM in collaboration with ICCVAM and its international collaborators in Japan, the EU, and Canada conducts research studies to evaluate the scientific validity of proposed new safety testing methods. NICEATM and ICCVAM also conduct international scientific peer review evaluations of proposed safety methods, and forward recommendations on scientific valid methods to Federal agencies, which must adopt the proposed methods or provide a basis for not adopting it. NICEATM and ICCVAM also organize scientific workshops to evaluate the current state of the science on a wide range of toxicological and other safety endpoints.
|
|
Interagency Group on Alzheimer''s Disease and Related Dementias for implementation of the National Alzheimer''s Project Act
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, FDA, HRSA
|
NIA
|
This interagency group was established by HHS in response to the Congressional directive to address Alzheimer''s disease. Under the National Alzheimer''s Project Act, HHS created three sub-groups on Research, Long Term Services, and Clinical Services. The Veteran''s Administration, National Science Foundation, and Department of Defense are also involved in this effort.
|
|
Interagency Midazolam Product Coordination Team
|
Committee, Work group, Advisory group, or Task Force
|
FDA, OS
|
NINDS, NIAID
|
HHS-led effort to facilitate activities, both research and regulatory, related to the FDA approval of midazolam for use in treating nerve agent exposure.
|
|
Interagency Modeling and Analysis Group (IMAG)
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIBIB, CSR, FIC, NCATS, NCI, NHGRI, NHLBI, NIA, NIAID, NIAMS, NICHD, NIDA, NIDCD, NIDDK, NIEHS, NIGMS, NIMH, NINDS, NLM, OD/DPCPSI/OBSSR
|
The Interagency Modeling and Analysis Group (IMAG) is comprised of program directors from ten government agencies in the U.S. and Canada, including the National Institutes of Health (NIH), the National Science Foundation (NSF), Department of Energy (DOE), Department of Defense (DOD), the United States Department of Agriculture (USDA), the Canadian federal research network for Mathematics of Information Technology and Complex Systems (MITACS), the National Aeronautics and Space Administration (NASA), the United States Department of Veterans Administration (USDVA), the Food and Drug Administration (FDA), and the Intelligence Advanced Research Projects Activity (IARPA). The purpose of IMAG is to bring together program officers who have a shared interest in supporting modeling and analysis methods in biomedical, biological and behavioral systems. IMAG has promoted and supported a wide variety of modeling over the past 10 years, notably the multi-scale modeling (MSM) initiative, which was originally a multi-agency funding opportunity announcement and continued on by different IMAG agencies through separate funding opportunity announcements. The MSM Consortium Meeting scheduled for 2013 was cancelled due to the government shutdown.
|
|
Interagency Pain Research Coordinating Committee (IPRCC)
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, FDA, IHS, OS, SAMHSA
|
NINDS, NCCAM, NIDA, NIDCR, NINR
|
The Interagency Pain Research Coordination Committee (IPRCC) was mandated by the Affordable Care Act to coordinate pain research activities across the government. The initial charge to the committee includes: 1) develop a summary of major advances in pain care research supported by Federal Agencies relevant to the diagnosis, prevention, and treatment of pain; 2) identify critical gaps and duplications in basic and clinical pain research across Federal Agencies; 3) make recommendations on how best to disseminate information on pain care; and 4) make recommendations on how to expand public-private partnerships to expand collaborative cross-cutting research. Federal and non-federal committee representatives and NIH staff developed a survey to address item 1 above and performed a portfolio analysis to address item 2 above. The committee was charged in 2012 with an additional task: to create a comprehensive, population health level strategy for pain prevention, treatment, management, and research. Volunteers from the IPRCC and professional associations established a working group to address the 2012 charge to the committee.
|